Back to Search
Start Over
Bristol-Myers Squibb: Though the star is bright, there are too many headwinds to ignore
- Source :
- Plus Company Updates. December 23, 2023
- Publication Year :
- 2023
-
Abstract
- Bristol-Myers Squibb Company (NYSE:BMY) has been facing a loss of exclusivity issue with its leading product, Revlimid, leading to a significant decline in annualized sales to $5.5B in 2023. The [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.777700588